In the past decade, BET inhibitors, a prominent category of epigenetic drugs targeting the BET domain, which are bromodomain-containing proteins with well-established roles in gene regulation via histone modification and chromatin remodeling (Fujisawa and Filippakopoulos, 2017), have been successfully developed for various cancer therapies, including hematological tumors and the comparatively uncommon nuclear protein in testis (NUT) midline carcinomas (Filippakopoulos et al., 2010; Gallenkamp et al., 2014). This evidence concerns the gene DNER and cancer.